FSA
IMDX

Fort Sheridan Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Fort Sheridan Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,750
Closed -$99K – 187
2022
Q3 		$99K Hold
6,750
– – 0.03% 176
2022
Q2 		$121K Hold
6,750
– – 0.04% 174
2022
Q1 		$201K Hold
6,750
– – 0.06% 173
2021
Q4 		$293K Buy
6,750
+1,250
+23% +$71.9K 0.08% 155
2021
Q3 		$392K Buy
5,500
+50
+0.9% +$4.6K 0.13% 119
2021
Q2 		$626K Buy
5,450
+300
+6% +$29.3K 0.21% 86
2021
Q1 		$535K Buy
+5,150
New +$489K 0.21% 75

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fort Sheridan Advisors's IMDX Position: Q4 2022 in Review

Fort Sheridan Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q4 2022, closing a stake of 6,750 shares — an estimated $99K sold.

Fort Sheridan Advisors first reported a position in IMDX in Q1 2021 and held it in 7 quarters. The position peaked at $626K in Q2 2021. 58 funds tracked by Wall St. Rank hold IMDX as of Q4 2022.

  • Fort Sheridan Advisors reported no remaining Insight Molecular Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Fort Sheridan Advisors sold 6,750 Insight Molecular Diagnostics shares in Q4 2022, an estimated $99K.
  • Fort Sheridan Advisors first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 7 quarters.
  • Fort Sheridan Advisors's Insight Molecular Diagnostics position peaked at $626K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2022.

Based on Fort Sheridan Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.